64 Results for "

L-dopa

" in MedChemExpress (MCE) Product Catalog:
Products (64)

64 Results for "L-dopa" in MCE Product Catalog:

35
35 Publications Verification
Cat. No.: HY-N0304
CAS No.: 59-92-7
Synonyms: Levodopa; 3,4-Dihydroxyphenylalanine
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
loading...
    loading...
35
35 Publications Verification
Cat. No.: HY-N0304A
CAS No.: 63302-01-2
Synonyms: Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-B0404A
CAS No.: 14919-77-8
Synonyms: Ro 4-4602 hydrochloride
Target:  

Pyruvate Kinase

Research Areas:  

Neurological Disease Cancer

Benserazide hydrochloride (Serazide) is an aromatic L-amino acid decarboxylase (AADC) and L-DOPA decarboxylase inhibitor. Benserazide hydrochloride is also a PKM2 inhibitor. Benserazide hydrochloride directly binds to and blocks PKM2 enzyme activity, leading to inhibition of aerobic glycolysis concurrent up-regulation of OXPHOS. Benserazide hydrochloride can be used for the study of Parkinson's disease and melanoma .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-121275
CAS No.: 322-35-0
Synonyms: Ro 4-4602
Target:  

Pyruvate Kinase

Research Areas:  

Neurological Disease Cancer

Benserazide is an aromatic L-amino acid decarboxylase (AADC) and L-DOPA decarboxylase inhibitor. Benserazide is also a PKM2 inhibitor. Benserazide directly binds to and blocks PKM2 enzyme activity, leading to inhibition of aerobic glycolysis concurrent up-regulation of OXPHOS. Benserazide can be used for the study of Parkinson's disease and melanoma .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-15257
CAS No.: 543906-09-8
Purity:  99.88%
Synonyms: AFQ056
Target:  

mGluR

Research Areas:  

Neurological Disease

Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active mGluR5 antagonist, with an IC50 of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease . Mavoglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N2278
CAS No.: 99217-63-7
Synonyms: Leachianone E
Kushenol A (Leachianone E) is isolated from the root of Sophora flavescent. Kushenol A is a non-competitive tyrosinase inhibitor to block the conversion of L-tyrosine to L-DOPA, shows IC50 and Kivalues of 1.1 μM and 0.4 μM, respectively . Kushenol A is a flavonoid antioxidant, has inhibitory effects on alpha-glucosidase (IC50: 45 μM; Ki: 6.8 μM) and β-amylase . Kushenol A is confirmed as potential inhibitors of enzymes targeted by cosmetics for skin whitening and aging .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P1335
CAS No.: 103429-32-9
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P1335A
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0304R
CAS No.: 59-92-7
Synonyms: Levodopa (Standard); 3,4-Dihydroxyphenylalanine (Standard)
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-113468A
CAS No.: 300-48-1
Purity:  99.16%
Synonyms: 3-Methoxy-L-tyrosine; 3-O-Methyl-L-dopa
3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0304S2
CAS No.: 586971-29-1
L-DOPA- 13C is the 13C labeled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18654
CAS No.: 1235318-89-4
Target:  

mGluR

Research Areas:  

Neurological Disease

ADX88178 is an orally active, blood-brain barrier-penetrant, selective positive allosteric modulator of mGluR4, with an EC50 of 3.5 nM against hmGluR4. ADX88178 modulates mGlu4 activity, enhances glutamate-mediated receptor activation, and increases the apparent affinity of glutamate for the receptor. ADX88178 reverses haloperidol-induced catalepsy, potentiates the effects of levodopa (L-DOPA) and quinpirole, but fails to alleviate established abnormal involuntary movements, does not exacerbate L-DOPA-induced dyskinesia, and does not affect forelimb akinesia when administered alone. ADX88178 can be used in research related to L-DOPA-induced dyskinesia and Parkinson's disease .
loading...
    loading...
Cat. No.: HY-162666
CAS No.: 3038770-25-8
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

TMEM175 modulator 1 (compound 47) is a TMEM175 modulator.TMEM175 modulator 1 modulates activity of the lysosomal potassium ion channel TMEM175.TMEM175 modulator 1 can be used for the research of parkinson’s disease, dementia, alzheimer’s disease, l-dopa induced dyskinesia .
loading...
    loading...
Cat. No.: HY-116016
CAS No.: 37178-37-3
Purity:  99.00%
Synonyms: L-dopa ethyl ester; Levodopa ethyl ester
Research Areas:  

Neurological Disease

Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .
loading...
    loading...
Cat. No.: HY-132392S
CAS No.: 53587-29-4
Purity:  98.80%
L-DOPA-2,5,6-d3 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain .
loading...
    loading...
Cat. No.: HY-113468AS
CAS No.: 586954-09-8
Purity:  ≥99.0%
Synonyms: 3-Methoxy-L-tyrosine-d3; 3-O-Methyl-L-dopa-d3
3-O-Methyldopa-d3 (3-Methoxy-L-tyrosine-d3) is deuterium labeled 3-O-Methyldopa (HY-113468A). 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .
loading...
    loading...
Cat. No.: HY-113357
CAS No.: 588-30-7
Purity:  99.84%
m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .
loading...
    loading...
Cat. No.: HY-B0927
CAS No.: 118-08-1
Synonyms: (-)-β-Hydrastine; (1R,9S)-β-Hydrastine
Hydrastine ((-)-β-Hydrastine; (1R,9S)-β-Hydrastine) is a selective competitive inhibitor of tyrosine hydroxylase (TH), inhibiting dopamine biosynthesis (IC50=20.7 μM, PC12 cells). Hydrastine also inhibits the organic cation transporter OCT1 (IC50=6.6 μM). Hydrastine may cause neuronal toxicity through mitochondrial dysfunction rather than oxidative stress damage, and can aggravate cell apoptosis when combined with L-DOPA. Hydrastine can be used to study Parkinson's disease-related dopaminergic neuronal damage .
loading...
    loading...
Cat. No.: HY-N0304S
CAS No.: 713140-75-1
Synonyms: Levodopa-d6; 3,4-Dihydroxyphenylalanine-d6
L-DOPA-d6 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
loading...
    loading...
Cat. No.: HY-141647
CAS No.: 1614253-58-5
Research Areas:  

Others

18F-Labeled L-dopa precursor is a precursor for synthesis of 18F-labeled L-dopa .
loading...
    loading...